[go: up one dir, main page]

HK1111604A1 - Dosage form containing oxycodone and naloxone - Google Patents

Dosage form containing oxycodone and naloxone Download PDF

Info

Publication number
HK1111604A1
HK1111604A1 HK08102490.3A HK08102490A HK1111604A1 HK 1111604 A1 HK1111604 A1 HK 1111604A1 HK 08102490 A HK08102490 A HK 08102490A HK 1111604 A1 HK1111604 A1 HK 1111604A1
Authority
HK
Hong Kong
Prior art keywords
naloxone
oxycodone
mean
oxn
max
Prior art date
Application number
HK08102490.3A
Other languages
German (de)
English (en)
Chinese (zh)
Other versions
HK1111604B (en
Inventor
Petra Leyendecker
Michael Hopp
Kevin Smith
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1111604(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of HK1111604A1 publication Critical patent/HK1111604A1/en
Publication of HK1111604B publication Critical patent/HK1111604B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (3)

  1. Forme posologique pharmaceutique à libération prolongée comprenant 40 mg d'oxycodone ou d'un de ses sels pharmaceutiquement acceptables et 20 mg de naloxone ou d'un de ses sels pharmaceutiquement acceptables, l'oxycodone ou un de ses sels pharmaceutiquement acceptables et la naloxone ou un de ses sels pharmaceutiquement acceptables étant présents en un rapport de 2:1 en poids, pour une utilisation dans le traitement de la douleur moyenne à grave et de syndromes de dysfonctionnement intestinal dus aux opioïdes apparaissant au cours de à thérapie contre la douleur, ledit syndrome de dysfonctionnement intestinal, dû aux opioïdes étant la constipation, et d'événements néfastes, lesdits événements néfastes étant des événements néfastes caractéristiques de la naloxone choisis dans le groupe consistant en la douleur abdominale, les crampes et la diarrhée.
  2. Forme posologique pharmaceutique suivant la revendication 1, destinée à être utilisée dans le traitement de la douleur moyenne à grave et des syndromes de dysfonctionnement intestinal dus aux opioïdes apparaissant au cours de la thérapie contre la douleur, ledit syndrome de dysfonctionnement intestinal dû aux opioïdes étant la constipation, et d'événements néfastes, lesdits événements néfastes étant des événements néfastes caractéristiques engendrés par la naloxone choisis dans le groupe consistant en la douleur abdominale, les crampes et la diarrhée, dans laquelle ledit sel pharmaceutiquement acceptable est le chlorhydrate, sulfate, bisulfate, tartrate, nitrate, citrate, bitatrate, phosphate, malate, maléate, bromhydrate, acide iodhydrique, fumarate ou succinate.
  3. Forme posologique pharmaceutique suivant la revendication 1 ou 2, destinée à être utilisée dans le traitement de la douleur moyenne à grave et des syndromes de dysfonctionnement intestinal dus aux opioïdes apparaissant au cours de la thérapie contre la douleur, ledit syndrome de dysfonctionnement intestinal dû aux opioïdes étant la constipation, et d'événements néfastes, lesdits événements néfastes étant des événements néfastes caractéristiques engendrés par la naloxone choisis dans le groupe consistant en la douleur abdominale, les crampes et la diarrhée, ladite forme posologique ayant été formulée pour l'application orale.
HK08102490.3A 2005-02-28 2006-02-28 Dosage form containing oxycodone and naloxone HK1111604B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05004377.7 2005-02-28
EP05004377A EP1695700A1 (fr) 2005-02-28 2005-02-28 Forme posologique contenant de l'oxycodone et de la naloxone
PCT/EP2006/060341 WO2006089973A2 (fr) 2005-02-28 2006-02-28 Forme galenique renfermant de l'oxycodone et de la naloxone

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK11104765.2A Division HK1150754A (en) 2005-02-28 2008-03-04 Dosage form containing oxycodone and naloxone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK11104765.2A Addition HK1150754A (en) 2005-02-28 2008-03-04 Dosage form containing oxycodone and naloxone

Publications (2)

Publication Number Publication Date
HK1111604A1 true HK1111604A1 (en) 2008-08-15
HK1111604B HK1111604B (en) 2011-10-21

Family

ID=

Also Published As

Publication number Publication date
DK200700248U3 (da) 2008-02-08
CA2960011A1 (fr) 2006-08-31
EP2962686B1 (fr) 2019-04-10
JP2014169303A (ja) 2014-09-18
WO2006089973A3 (fr) 2006-12-28
EP1855657A2 (fr) 2007-11-21
CY1111967T1 (el) 2015-11-04
ATE517611T1 (de) 2011-08-15
RS51984B (sr) 2012-02-29
FI7750U1 (fi) 2008-01-22
WO2006089973A2 (fr) 2006-08-31
MX2007010494A (es) 2008-01-16
US20140031382A1 (en) 2014-01-30
EP2258353A3 (fr) 2012-05-09
NZ588875A (en) 2012-02-24
IL185514A0 (en) 2008-01-06
ES2370409T3 (es) 2011-12-15
DE202006020095U1 (de) 2007-11-08
EP1855657B1 (fr) 2011-07-27
EP2962686A1 (fr) 2016-01-06
AU2009201019A1 (en) 2009-04-02
US20110172259A1 (en) 2011-07-14
US20080145429A1 (en) 2008-06-19
UA93543C2 (ru) 2011-02-25
RU2007135991A (ru) 2009-04-10
PL1855657T3 (pl) 2012-03-30
EP3578173A1 (fr) 2019-12-11
CA2768075A1 (fr) 2006-08-31
JP2008531650A (ja) 2008-08-14
IL196539A0 (en) 2011-07-31
US20180008593A1 (en) 2018-01-11
AU2009201019B2 (en) 2011-05-26
EP3578173B1 (fr) 2022-10-26
HRP20110775T1 (hr) 2011-11-30
CA2599156C (fr) 2012-05-01
SI1855657T1 (sl) 2011-11-30
PT1855657E (pt) 2011-10-31
RU2428985C2 (ru) 2011-09-20
DK1855657T3 (da) 2011-10-17
KR20070107805A (ko) 2007-11-07
AU2006217870B2 (en) 2008-12-18
ME01262B (fr) 2013-06-20
AU2006217870A1 (en) 2006-08-31
DK200700248U1 (da) 2007-12-14
DE19167974T1 (de) 2021-12-30
BRPI0607975A2 (pt) 2009-10-27
EP2258353A2 (fr) 2010-12-08
EP1695700A1 (fr) 2006-08-30
CA2599156A1 (fr) 2006-08-31
FIU20070153U0 (fi) 2007-04-13
US20120225901A1 (en) 2012-09-06
JP6235962B2 (ja) 2017-11-22
CN104027297A (zh) 2014-09-10
CN101128191A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
EP2962686B1 (fr) Forme posologique contenant de l'oxycodone et de la naloxone
EP2405915B1 (fr) Compositions pharmaceutiques à libération immédiate comportant de l'oxycodone et de la naloxone
EP2317991B1 (fr) Utilisation d'antagonistes opioïdes pour le traitement d'une rétention urinaire
US20120270848A1 (en) Novel Compositions and Therapeutic Methods Using Same
HK1219669B (en) Dosage form containing oxycodone and naloxone
HK1219669A1 (en) Dosage form containing oxycodone and naloxone
HK1111604B (en) Dosage form containing oxycodone and naloxone
HK1150754A (en) Dosage form containing oxycodone and naloxone
HK1157643B (en) Use of opioid antagonists for treating urinary retention
HK1157643A (en) Use of opioid antagonists for treating urinary retention

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190228